U.S. Markets closed

Akari Therapeutics, Plc (AKTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9200-0.0300 (-1.54%)
At close: 4:00PM EDT

Akari Therapeutics, Plc

75/76 Wimpole Street
London W1G 9RT
United Kingdom
44 20 8004 0270

Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Dr. Ray PrudoExec. Chairman618kN/A1945
Mr. Clive RichardsonCOO, CEO & Director808.23kN/A1965
Dr. Torsten HombeckChief Financial Officer309.86kN/A1970
Dr. Miles NunnChief Scientific OfficerN/AN/AN/A
Annie MackFinancial ControllerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Corporate Governance

Akari Therapeutics, Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.